Log in

Sunesis Pharmaceuticals Stock Forecast, Price & News

+0.19 (+16.24 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $1.36
50-Day Range
MA: $2.23
52-Week Range
Now: $1.36
Volume3.43 million shs
Average Volume740,936 shs
Market Capitalization$24.61 million
P/E RatioN/A
Dividend YieldN/A
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Read More
Sunesis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SNSS



Sales & Book Value

Annual Sales$2.07 million
Book Value$1.42 per share


Net Income$-23,330,000.00


Market Cap$24.61 million
Next Earnings Date11/10/2020 (Estimated)
+0.19 (+16.24 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNSS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions

How has Sunesis Pharmaceuticals' stock been impacted by Coronavirus?

Sunesis Pharmaceuticals' stock was trading at $6.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SNSS shares have decreased by 78.4% and is now trading at $1.36.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Sunesis Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Sunesis Pharmaceuticals

When is Sunesis Pharmaceuticals' next earnings date?

Sunesis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Sunesis Pharmaceuticals

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced its earnings results on Tuesday, August, 11th. The biopharmaceutical company reported ($0.60) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.60).
View Sunesis Pharmaceuticals' earnings history

When did Sunesis Pharmaceuticals' stock split? How did Sunesis Pharmaceuticals' stock split work?

Sunesis Pharmaceuticals shares reverse split on Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of Sunesis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SNSS?

4 Wall Street analysts have issued 1-year price objectives for Sunesis Pharmaceuticals' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Sunesis Pharmaceuticals' share price to reach $7.50 in the next year. This suggests a possible upside of 451.5% from the stock's current price.
View analysts' price targets for Sunesis Pharmaceuticals

Are investors shorting Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totaling 588,300 shares, a decline of 93.5% from the August 31st total of 8,990,000 shares. Based on an average daily volume of 1,650,000 shares, the short-interest ratio is presently 0.4 days. Currently, 3.3% of the shares of the stock are sold short.
View Sunesis Pharmaceuticals' Short Interest

Who are some of Sunesis Pharmaceuticals' key competitors?

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX).

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the following people:
  • Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)
  • Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)
  • Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)
  • Mr. Gene C. Jamieson, VP of Technical Operations
  • Dr. Judith A. Fox, Chief Scientific Officer

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

Who are Sunesis Pharmaceuticals' major shareholders?

Sunesis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (2.33%), UBS Group AG (0.13%) and Jane Street Group LLC (0.12%). Company insiders that own Sunesis Pharmaceuticals stock include Aisling Capital Iv, Lp, Tina Gullotta and William P Quinn.
View institutional ownership trends for Sunesis Pharmaceuticals

Which institutional investors are selling Sunesis Pharmaceuticals stock?

SNSS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL.
View insider buying and selling activity for Sunesis Pharmaceuticals

Which institutional investors are buying Sunesis Pharmaceuticals stock?

SNSS stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and UBS Group AG. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Aisling Capital Iv, Lp, Tina Gullotta, and William P Quinn.
View insider buying and selling activity for Sunesis Pharmaceuticals

How do I buy shares of Sunesis Pharmaceuticals?

Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of SNSS stock can currently be purchased for approximately $1.36.

How big of a company is Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals has a market capitalization of $24.61 million and generates $2.07 million in revenue each year. The biopharmaceutical company earns $-23,330,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.

What is Sunesis Pharmaceuticals' official website?

The official website for Sunesis Pharmaceuticals is www.sunesis.com.

How can I contact Sunesis Pharmaceuticals?

Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.